Shannon Hopson, DO
Endocrinology
New patients by referral
“The best part of being an endocrinologist is I really get to know my patients.”
Dr. Hopson provides general endocrinology care, and is inspired by the latest technology in diabetes management. She has a special interest in meditation and mindfulness to help her patients cope with the stress of work, family, and living with a chronic medical condition. Dr. Hopson also provides transgender hormone therapy.
Language(s) - English
As an endocrinologist, Dr. Shannon Hopson knows many patients are not all too happy having to go to her. But that only makes it all the sweeter in the end. “I am proud of the relationships I have built with my patients, in particular with those who were reluctant to keep their first appointment – especially when we can reflect on the progress that has been made and the improvements they’ve been able to make in their health as a result of working with me.”
She had been always interested in pursuing a career in medicine but had not even considered endocrinology until a rotation during residency. “Within a week, I fell in love with it,” she says. “Learning to interpret labs and adjust medications, and then figuring out diabetes management was fun and rewarding.”
Dr. Hopson says she is very honest and straightforward, and her patients would describe her as a good listener and empathetic. “I consider myself a coach – it’s my job to meet the patient where he or she is, hear their story, and then offer suggestions for treatment. I will always give my honest opinion on what treatment options I consider to be the best, while recognizing that my patient is ultimately the one who makes the decision on what course of action we will take.”
An amateur photographer, Dr. Hopson loves to travel, hike and spend time outdoors with her two boys.
Fellowship
Endocrinology, Diabetes and Metabolism, Medical University of South Carolina, Charleston, SC, 2004
Residency
Internal Medicine, Greenville Hospital System, Greenville, SC, 2002
Education
Doctor of Osteopathic Medicine, College of Osteopathic Medicine, Oklahoma State University, Tulsa, OK, 1999
Experience
Medical Director of Diabetes and Endocrinology, CaroMont Regional Medical Center, Gastonia, NC, 2004-2019; Endocrinologist, Endocrinology Associates, Gastonia, NC, and Lake Wylie, SC, 2004-2019
Certification
American Board of Internal Medicine in Endocrinology, Diabetes and Metabolism
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared with Placebo in Participants with Obesity or Overweight, with and without Type 2 Diabetes, J2A MC GZPO, J2A MC GZP1, J2A MC GZP2, May 2025, Phase III
A Phase 3, Randomized, Multicenter, Open label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared with Semaglutide Once Weekly in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Metformin, with or without SGLT2 Inhibitor, TRANSCEND T2D 2, J1I MC GZBZ, Eli Lilly, March 2024, Phase III
A Phase 3, Randomized, Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared with Placebo in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Diet and Exercise Alone, ACHIEVE 1, J2A MC GZGT, Eli Lilly, September 2023, Phase III
A Phase 3, Randomized, Open Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared with Oral Semaglutide in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Metformin, ACHIEVE 3, J2A MC GZGU, Eli Lilly, October 2023, Phase III
A Randomized, Open Label, Parallel Group, Two Arm, Phase 4 Study to Evaluate the Long Term Efficacy and Safety of Tirzepatide Compared with Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes, SURPASS EARLY, I8F MC GPHE, Eli Lilly, July 2022, Phase IV
Efficacy and Safety of Tirzepatide Once Weekly in Participants with Type 2 Diabetes Who Have Obesity or Are Overweight, A Randomized, Double Blind, Placebo Controlled Trial, SURMOUNT 2, I8F MC GPHL, Eli Lilly, April 2021, Phase III
Efficacy and Safety of Once Daily Oral Semaglutide, 25 mg and 50 mg, Compared with 14 mg in Subjects with Type 2 Diabetes, NN9924 4635, Novo Nordisk, February 2021, Phase III
Hopson, PS and Clement-Bryant, L. 2009. Insulin Pump Therapy in Pregnancy: A Retrospective Review of a Community Based Clinic’s Experiences. Poster Presentation, 5th International Symposium on Diabetes and Pregnancy.
Patient Ratings
The Patient Rating score is an average of all responses to care provider related questions on the Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments From Patients
I really felt comfortable with the doctor. I have never had this type of visit. She was professional but certainly not stuffy She was down to earth and listened to me and educated me. Told me what was going on in my body, and work on this together
Dr. Hopson radiates confidence without ego. She recognizes a patient’s knowledge/lack of knowledge of their “issue” and neither talks down nor over their head in reaching consensus for treatment.
Dr Hopson is very knowledgeable of her chosen field of endocrinology I have respect for her understanding and her knowledge of of endocrine system for me she is great
Excellent experience. She is knowledgeable and personable, very skilled, sensitive to the needs of the patient.
Amazing! Listened to my need and explained everything to me.
Click on the appropriate link below to enter your provider’s telemedicine waiting room for your scheduled appointment.
